Hugues de Lavallade

机构：Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Foundation Trust · ORCID：0000-0002-4988-2564

发表论文 197 篇 · 总被引 7061 次 · h-index 36

代表论文

• Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial (2021 · The Lancet Haematology · 被引 59)
• Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia (2023 · Haematologica · 被引 15)
• Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (2022 · Blood · 被引 15)
• Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial (2024 · The Lancet Haematology · 被引 14)
• Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms (2024 · HemaSphere · 被引 14)
• Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy (2022 · Blood · 被引 13)